Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 1 Recruiting
57 enrolled
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Phase 1 Recruiting
32 enrolled
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
Phase 1 Completed
28 enrolled
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Phase 1 Completed
11 enrolled 9 charts
KETO-CARE
Phase 1 Completed
20 enrolled
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Phase 1 Completed
20 enrolled
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Phase 1 Completed
35 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Phase 1 Completed
9 enrolled 17 charts
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Phase 1 Terminated
31 enrolled
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Phase 1 Unknown
30 enrolled
Epi-PRIMED
Phase 1 Completed
8 enrolled
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Phase 1 Completed
9 enrolled
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase 1 Completed
9 enrolled
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1 Completed
24 enrolled
NAC
Phase 1 Terminated
27 enrolled
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Phase 1 Completed
14 enrolled
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Phase 1 Completed
13 enrolled
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Phase 1 Terminated
14 enrolled
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Phase 1 Completed
107 enrolled
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled